CBG(000009)2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥8,225,433,605.49, representing a decrease of 8.28% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2023 was ¥186,852,024.02, an increase of 22.65% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥238,222,209.75, up 58.85% from the previous year[4]. - Basic earnings per share for Q3 2023 was ¥0.0725, reflecting a growth of 22.88% year-on-year[4]. - The net profit for Q3 2023 was CNY 1,489,456,704.40, a decrease from CNY 1,558,784,901.19 in Q3 2022, representing a decline of approximately 4.4%[17]. - The total profit for Q3 2023 was CNY 1,909,710,596.36, compared to CNY 1,858,685,920.06 in Q3 2022, indicating a growth of about 2.8%[17]. - The operating profit for Q3 2023 was CNY 1,912,579,458.96, slightly higher than CNY 1,875,209,265.23 in Q3 2022, showing an increase of approximately 2.4%[17]. - The total comprehensive income for Q3 2023 was CNY 1,496,651,119.16, down from CNY 1,585,282,325.66 in Q3 2022, representing a decrease of approximately 5.6%[18]. Cash Flow - The net cash flow from operating activities for the year-to-date period reached ¥3,924,570,676.43, a significant increase of 1,820.89% compared to the same period last year[4]. - The net cash flow from operating activities for Q3 2023 was ¥3,924,570,676.43, a significant improvement from a net outflow of ¥228,054,074.04 in Q3 2022[20]. - Total cash inflow from investment activities was ¥2,790,656,816.54, compared to ¥2,702,799,717.04 in the same period last year[20]. - The net cash flow from investment activities showed a loss of ¥1,949,288,105.46, an improvement from a loss of ¥3,649,689,361.48 in Q3 2022[20]. - Cash inflow from financing activities totaled ¥6,086,231,876.96, down from ¥12,409,939,796.56 in Q3 2022[20]. - The net cash flow from financing activities was negative at -¥1,976,766,556.51, compared to a positive flow of ¥4,166,008,995.66 in the previous year[20]. - The total cash and cash equivalents at the end of Q3 2023 amounted to ¥7,881,683,236.20, an increase from ¥6,377,775,854.83 at the end of Q3 2022[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥52,293,310,406.08, a decrease of 4.02% from the previous year-end[4]. - The total assets decreased to ¥50,278,681,050.20 from ¥52,385,798,596.69, a reduction of 4%[15]. - The total liabilities decreased to ¥29,962,565,922.47 from ¥33,542,017,842.73, a decline of 10.5%[15]. - The company reported a total asset value of ¥52,385,798,596.69 as of January 1, 2023, reflecting an increase from ¥52,293,310,406.08 at the end of 2022[23]. - The total liabilities rose from ¥33,450,764,548.03 at the end of 2022 to ¥33,542,017,842.73 as of January 1, 2023[23]. Equity - The equity attributable to shareholders at the end of the reporting period was ¥9,133,813,548.67, an increase of 7.76% compared to the previous year-end[4]. - The company’s total equity increased to ¥20,316,115,127.73 from ¥18,843,780,753.96, reflecting a growth of 7.8%[15]. - The company’s total equity attributable to shareholders increased slightly from ¥9,133,813,548.67 at the end of 2022 to ¥9,135,864,452.50 as of January 1, 2023[23]. Investment and Financing - The company increased its long-term borrowings by 82.45%, reaching ¥8,995,465,306.31 due to new long-term loans[7]. - The company reported a significant increase in long-term borrowings, which rose to ¥8,995,465,306.31 from ¥4,930,271,374.05, an increase of 82%[15]. - Interest income decreased by 69.90% to ¥8,301,218.20 compared to ¥27,574,921.59 in the same period last year due to the contraction of microloan business[8]. - Investment income fell by 59.00% to ¥175,858,733.30 from ¥428,963,478.75, primarily due to high investment returns from joint ventures in the previous year[8]. Impairment Losses - The company’s subsidiaries reported a significant reduction in credit impairment losses by 76.63% to -¥27,349,016.51, compared to -¥117,032,081.55 in the previous year[8]. - The company’s subsidiaries reported an increase in asset impairment losses by 228.15% to -¥69,447,034.73, attributed to increased inventory write-downs due to market conditions[8]. Other Agreements and Projects - The company completed the transfer of 59.469 million shares of Shenzhen Dafu Pharmaceutical Co., Ltd. at ¥4.38 per share to Hangzhou Yunbai Pharmaceutical Technology Co., Ltd.[11]. - The company signed a supplementary agreement for the urban renewal project in Longgang District, Shenzhen, focusing on "urban renewal + benefit coordination"[11]. - A joint venture agreement was amended to adjust the construction site for a new energy lithium battery anode material project in Indonesia[11].